Skip to Content

Promising Effect of Zolbetuximab and mFOLFOX6 Combination For Gastroesophageal Junction Adenocarcinoma

The SPOTLIGHT study, presented at ASCO GI, indicates promising effects of combining Zolbetuximab with mFOLFOX6 chemotherapy as first-line treatment for people with advanced gastroesophageal junction adenocarcinoma resistant to surgery. Kohei Shitara from the National Cancer Center Hospital East in Chiba, Japan, presents the results in this MEDtalk.

Kohei Shitara

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top